DJIA 17,026.16 -13.33 -0.08%
NASDAQ 4,537.41 5.31 0.12%
S&P 500 1,989.98 -2.39 -0.12%
market minute promo

AbbVie Inc. (NYSE: ABBV)

54.71 -0.25 (-0.45%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

ABBV $54.71 -0.45%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $54.87
Previous Close $54.96
Daily Range $54.36 - $54.98
52-Week Range $42.26 - $58.27
Market Cap $87.1B
P/E Ratio 21.30
Dividend (Yield) $1.68 (3.1%)
Ex-Dividend Date
Dividend Pay Date
07/11/14
08/15/14
Volume 4,780,153
Average Daily Volume 14,570,736
Current FY EPS $3.16

Sector

Industry

AbbVie Inc. (ABBV) Description

AbbVie Inc. Website: http://www.abbvie.com/

News & Commentary Rss Feed

3 Reasons Gilead Science, Inc.’s Stock Could Rise

Hepatitis C sales, a smart acquisition, and the potential for a dividend could all increase Gilead Sciences' stock price further.

Pre-Market Most Active for Aug 22, 2014 : ABBV, BAC, QQQ, CRM, AAPL, TVIX, JRJC, DYN, VOD, XIV, NOK

Pre-Market Most Active for Aug 22, 2014 : ABBV, BAC, QQQ, CRM, AAPL, TVIX, JRJC, DYN, VOD, XIV, NOK, BP

Wall Street Breakfast: Restrictions Imposed On Citigroup's Hedge Fund Sales

GlaxoSmithKline's (GSK) Arnuity Ellipta Approved by FDA - Analyst Blog

GlaxoSmithKline's (GSK) Arnuity Ellipta Approved by FDA - Analyst Blog

Achillion Attains 52-Week High on ACH-3102 Patent Protection - Analyst Blog

Jim Cramer's Stop Trading: Don't Worry About Gilead Sciences

Novartis to Invest $35M in Gamida Cell for 15% Equity - Analyst Blog

Novartis to Invest $35M in Gamida Cell for 15% Equity - Analyst Blog

GlaxoSmithKline: The Bad Isn't All That Bad

3 Drugs Stocks Dragging The Industry Down

Biogen Strengthens MS Portfolio with Plegridy FDA Approval - Analyst Blog

See More ABBV News...